Condition
Neoplasm, Residual
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Terminated1
Unknown1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02169609Phase 2Completed
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
NCT03441464Phase 1Terminated
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
NCT05167604Unknown
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
NCT01594892Not ApplicableCompleted
Fractionated Radiosurgery for Painful Spinal Metastases
NCT02900950Not ApplicableCompleted
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
Showing all 5 trials